Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

StockNews.com

Check Out What Whales Are Doing With AMGN

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Biotechs with $1 Billion in Cash

Worried about a recession? These cashed-up biotech stocks aren't sweating it.

The Street

Here Are The 5 Best Dow Jones Stocks So Far This Year Amid Market Sell-Off

Chevron is well off its June peak, but is still the top Dow Jones stock performer so far in 2022 amid a brutal market sell-off.

Investors Business Daily

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of $130.40 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Investors Business Daily

How Is The Market Feeling About Amgen?

Amgen's (NASDAQ:AMGN) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 3.54% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion.

Benzinga

Did Mirati Therapeutics Just Leapfrog Amgen?

The ongoing duel for KRAS inhibitor dominance takes yet another turn.

The Street

The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed

Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.

Investors Business Daily

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion.

Benzinga

Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash

Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyst Ratings for Amgen

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

The Street

Amazon, Clorox on Bank of America List of Stocks Hurt by Inflation

Inflation is raging, with consumer prices soaring 8.3% in the 12 months through April.

Benzinga

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all regular shares that are available for trading.

StockNews.com

2 Buy-Rated Dow Jones Stocks to Add to Your Portfolio Now

Investors’ concerns over a potential recession due to the Fed’s policy measures to control inflation wreaked havoc on the stock market over the past few weeks. However, the recovery of the major stock-market indexes in the last trading session indicates that the market could be leveling off. With the possibility…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Executives Sell More Than $220M Of 3 Stocks

US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

This Is What Whales Are Betting On Amgen

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades.

Benzinga

Analyzing Amgen's Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of all regular shares that are available for trading.

Benzinga

Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of $124.75 billion.

Benzinga

Check Out What Whales Are Doing With AMGN

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.

Benzinga

Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at $235.12 per share. A move to $260.00 would account for a 10.58% increase from the current…

Benzinga

Amgen's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.

1 … 11 12 13 14

People

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.